Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 31, 2020

View Archived Issues

Activity against AML seen in vitro and in vivo with LSD1 inhibitor CPI-482

Phase II results reported for AXL inhibitor bemcentinib in patients failing hypomethylating agents

Sulanda approved in China for non-pancreatic NETs

Saroglitazar magnesium approved in India for NAFLD

Altimmune initiates phase II trial of HepTcell for chronic hepatitis B

Codiak reports initial phase I data on exoIL-12 for CTCL

Arcturus selects ARCT-032 as development candidate for cystic fibrosis

FDA clears LyGenesis' IND for phase IIa study of cell therapy for end-stage liver disease

Ascendis files IND for TransCon TLR7/8 agonist

Lanzhou University synthesizes siRNAs targeting OLFML2A

New phase I/II study explores use of TY-101 for solid tumors and lymphomas

New AXL/Mer/c-Met/VEGFR-2 inhibitors discovered at Exelixis

Mirati Therapeutics describes new polycomb protein EED inhibitors

Orexin receptor antagonists patented by Hager Biosciences

University of California, Oakland presents inhibitors of activities caused by MECP2 gene mutations

Preclinical evaluation of SPR-519, a novel dual PI3K-alpha and mTOR kinase inhibitor

UBA1 gene mutations linked to novel adult-onset rheumatic disease

ImmunoPrecise Antibodies joins consortium to develop SARS-CoV-2-specific therapeutic nanomedicine

Atlas maps cleaned-up tumor microbiomes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...